Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 94 for:    Recruiting, Not yet recruiting, Active, not recruiting Studies | marijuana | United States

Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03614637
Recruitment Status : Recruiting
First Posted : August 3, 2018
Last Update Posted : December 25, 2018
Sponsor:
Collaborator:
John Templeton Foundation
Information provided by (Responsible Party):
Duke University

Brief Summary:
This is a follow-up project to a proof-of-concept study to determine if Cannabis use in male humans is associated with changes in deoxyribonucleic acid (DNA) methylation profile of sperm. This proposal will examine the epigenome of sperm from men actively using Cannabis before and after a period of Cannabis abstinence. The results will be compared to control non-users.

Condition or disease Intervention/treatment
Cannabis Use Other: Cannabis use abstinence for 11 weeks

Detailed Description:
This project involves recruitment of 72 healthy males between the ages of 18 and 40 years. Forty eight of the participants will be regular cannabis users with a self-reported frequency of at least once weekly over the past 6 months, and a control group of twenty four cannabis non-users. Cannabis users will be asked to quit using cannabis for 11 weeks and will be required to attend 25 visits during the 11 week abstinence/contingency management period. Non-users will be asked to return to the clinic once a week for 11 weeks. Abstinence will be determined by self-report, qualitative urine rapid screening test at the clinic and quantitatively via Enzyme Immunoassay (EIA) analysis of THC (cannabinoids) and, by Liquid Chromatography Tandem Mass Spectrometry (LCMSMS) analysis of 11-nor-9-carboxy-∆ 9-tetrahydrocannabinol (THCCOOH) performed by an analytical lab contracted by the study team. Semen sample for both groups will be collected prior to the start of abstinence and after 11 weeks. Semen analysis and DNA methylation of sperm cells will be compared.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 72 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells: Effects of Exposure and Abstinence (Component 1)
Actual Study Start Date : November 7, 2017
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Group/Cohort Intervention/treatment
Cannabis User Group
Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
Other: Cannabis use abstinence for 11 weeks
Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.

Non-Cannabis User Group
Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime



Primary Outcome Measures :
  1. Group differences in sperm DNA methylation profiles between user and non-user group [ Time Frame: Baseline ]
    We will compare the overall DNA methylation profiles in sperm cells of user and non-user group to replicate findings in the pilot study.

  2. Within group change in DNA methylation profiles from baseline to after 11 weeks of Cannabis abstinence [ Time Frame: Baseline to after 11 weeks of abstinence from Cannabis use. ]
    We will compare the overall DNA methylation profiles in sperm cells after an 11 week period of Cannabis abstinence in the user group


Secondary Outcome Measures :
  1. Group differences in the sperm analysis profile between user and non-user group [ Time Frame: Baseline ]
    We will compare the overall sperm analysis profile of user versus non-user group to replicate findings in the pilot study

  2. Within group change in sperm analysis profile from baseline to after eleven weeks of Cannabis abstinence [ Time Frame: Baseline to after 11 weeks of abstinence from Cannabis use ]
    We will compare sperm analysis profile after an eleven week period of Cannabis abstinence in the user group



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   We are looking at effects of Cannabis use in sperm cells.
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
72 healthy males between the ages of 18 and 40 years. Forty eight - regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months, Twenty four Cannabis non-users - control group
Criteria

Inclusion Criteria:

  • Male gender
  • Between the ages of 18-40 years, inclusive;
  • Free from significant medical/psychiatric conditions
  • Willingness to provide baseline semen sample and again at the end of study participation
  • Willingness to comply
  • Ability to communicate verbally and in written form in English.

For the CANNABIS USER group:

  • Self-reported Cannabis use of at least once weekly for past 6 months;
  • THC level of at least 50 ng/ml (EIA, non-creatinine adjusted value) and THCCOOH level of at least 15ng/ml (LCMSMS, non-creatinine adjusted value);
  • Positive result on urine rapid screening test for THC; and
  • Willingness to abstain from Cannabis for 11 weeks during the course of the study

For the CANNABIS NON-USER group:

  • Self-report of no Cannabis use in the past 6 months; fewer than 10 times lifetime;
  • THCCOOH level = 0 ng/ml; (EIA non-creatinine adjusted value) and
  • Negative result on urine rapid screening test.

Exclusion Criteria:

  • Positive result for any other drugs of abuse on urine rapid screening test (including cocaine, methamphetamine, opiates, benzodiazepines, and barbiturates); or use of nicotine or tobacco products;-Currently prescribed any psychoactive medication;
  • Current diagnosis of any significant psychiatric condition, including substance use disorders. For the user group, Cannabis Use Disorder that does not require immediate clinical attention in the opinion of the clinician/investigator will be allowed.
  • Score on the Marijuana Screening Inventory-X > 10;
  • Score on the Alcohol Use Disorders Identification Test > 8;
  • Expired breath CO reading of > 8 ppm at screening and throughout the study.
  • Expired Breath Alcohol Level of > 0.000 at screening.
  • Urinary cotinine level greater than 2- indicating urinary concentrations of > 30ng/ml cotinine at screening and throughout the study
  • Estimated IQ < 80 as assessed by the Kaufman Brief Intelligence Test, Second Edition; and
  • Unable to comply with study requirements or otherwise unsuitable for participation in the opinion of the study physician and/or study psychologist.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03614637


Contacts
Layout table for location contacts
Contact: Nilda Itchon-Ramos 9196810032 nilda.itchonramos@dm.duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke Child and Family Study Center Recruiting
Durham, North Carolina, United States, 27705
Contact: Nilda Itchon-Ramos    919-681-0032    nilda.itchonramos@dm.duke.edu   
Principal Investigator: Scott Kollins, PhD         
Sub-Investigator: John Mitchell, PhD         
Sponsors and Collaborators
Duke University
John Templeton Foundation

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT03614637     History of Changes
Other Study ID Numbers: Pro00086400
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: December 25, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Duke University:
Cannabis Abstinence Sperm Cells

Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders